Literature DB >> 20232379

Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.

Anne Masset1, Catherine Maillard, Nor Eddine Sounni, Nathalie Jacobs, Françoise Bruyére, Philippe Delvenne, Marlene Tacke, Thomas Reinheckel, Jean-Michel Foidart, Lisa M Coussens, Agnès Noël.   

Abstract

Angiogenesis, extracellular matrix remodeling and cell migration are associated with cancer progression and involve at least, the plasminogen activating system and its main physiological inhibitor, the plasminogen activator inhibitor-1 (PAI-1). Considering the recognized importance of PAI-1 in the regulation of tumor angiogenesis and invasion in murine models of skin tumor transplantation, we explored the functional significance of PAI-1 during early stages of neoplastic progression in the transgenic mouse model of multistage epithelial carcinogenesis (K14-HPV16 mice). We have studied the effect of genetic deletion of PAI-1 on inflammation, angiogenesis, lymphangiogenesis and tumor progression. In this model, PAI-1 deficiency neither impaired keratinocyte hyperproliferation or tumor development nor affected the infiltration of inflammatory cells and development of angiogenic or lymphangiogenic vasculature. We are reporting evidence for concomitant lymphangiogenic and angiogenic switches independent to PAI-1 status. Taken together, these data indicate that PAI-1 is not rate limiting for neoplastic progression and vascularization during premalignant progression, or that there is a functional redundancy between PAI-1 and other tumor regulators, masking the effect of PAI-1 deficiency in this long-term model of multistage epithelial carcinogenesis.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232379      PMCID: PMC3084626          DOI: 10.1002/ijc.25326

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  59 in total

Review 1.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

2.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

Authors:  L S Gutierrez; A Schulman; T Brito-Robinson; F Noria; V A Ploplis; F J Castellino
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

3.  A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells.

Authors:  Rashna D Balsara; Francis J Castellino; Victoria A Ploplis
Journal:  J Biol Chem       Date:  2006-06-19       Impact factor: 5.157

4.  Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1.

Authors:  Yabing Chen; Ralph C Budd; Robert J Kelm; Burton E Sobel; David J Schneider
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-05-18       Impact factor: 8.311

Review 5.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

Review 6.  PAI-1 - a potential therapeutic target in cancer.

Authors:  Peter A Andreasen
Journal:  Curr Drug Targets       Date:  2007-09       Impact factor: 3.465

7.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Authors:  Birgitte Vrou Offersen; Boye Schnack Nielsen; Gunilla Høyer-Hansen; Fritz Rank; Stephen Hamilton-Dutoit; Jens Overgaard; Peter A Andreasen
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.

Authors:  C M Maillard; C Bouquet; M M Petitjean; M Mestdagt; E Frau; M Jost; A M Masset; P H Opolon; F Beermann; M M Abitbol; J M Foidart; M J Perricaudet; A C Noël
Journal:  Carcinogenesis       Date:  2008-08-27       Impact factor: 4.944

9.  Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression.

Authors:  T Lifsted; T Le Voyer; M Williams; W Muller; A Klein-Szanto; K H Buetow; K W Hunter
Journal:  Int J Cancer       Date:  1998-08-12       Impact factor: 7.396

10.  PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma.

Authors:  Cynthia E Wilkins-Port; Craig E Higgins; Jennifer Freytag; Stephen P Higgins; J Andrew Carlson; Paul J Higgins
Journal:  J Biomed Biotechnol       Date:  2007-03-20
View more
  8 in total

1.  Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses.

Authors:  Miriam Fanjul-Fernández; Alicia R Folgueras; Antonio Fueyo; Milagros Balbín; María F Suárez; M Soledad Fernández-García; Steven D Shapiro; José M P Freije; Carlos López-Otín
Journal:  J Biol Chem       Date:  2013-04-02       Impact factor: 5.157

Review 2.  Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Authors:  Veronica R Placencio; Yves A DeClerck
Journal:  Cancer Res       Date:  2015-07-15       Impact factor: 12.701

3.  Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

Authors:  Hua Fang; Veronica R Placencio; Yves A DeClerck
Journal:  J Natl Cancer Inst       Date:  2012-09-13       Impact factor: 13.506

4.  Human papillomavirus oncoproteins induce a reorganization of epithelial-associated γδ T cells promoting tumor formation.

Authors:  Dorien Van Hede; Barbara Polese; Chantal Humblet; Anneke Wilharm; Virginie Renoux; Estelle Dortu; Laurence de Leval; Philippe Delvenne; Christophe J Desmet; Fabrice Bureau; David Vermijlen; Nathalie Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-10       Impact factor: 11.205

5.  A role for microRNA-155 expression in microenvironment associated to HPV-induced carcinogenesis in K14-HPV16 transgenic mice.

Authors:  Isabel Paiva; Rui M Gil da Costa; Joana Ribeiro; Hugo Sousa; Margarida Bastos; Ana Faustino-Rocha; Ana Faustino Carlos Rocha; Carlos Lopes; Paula A Oliveira; Rui Medeiros
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

Review 6.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

7.  Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model.

Authors:  Hideki Furuya; Kazukuni Hayashi; Yoshiko Shimizu; Nari Kim; Yutaro Tsukikawa; Runpu Chen; Yijun Sun; Owen T M Chan; Ian Pagano; Rafael Peres; Kanani Hokutan; Fumie Igari; Keith S Chan; Charles J Rosser
Journal:  J Transl Med       Date:  2020-02-05       Impact factor: 5.531

8.  Bone marrow-derived mesenchymal stem cells drive lymphangiogenesis.

Authors:  Ludovic Maertens; Charlotte Erpicum; Benoit Detry; Silvia Blacher; Bénédicte Lenoir; Oriane Carnet; Christel Péqueux; Didier Cataldo; Julie Lecomte; Jenny Paupert; Agnès Noel
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.